Lifecore Narrows Losses, Boosts Revenue Amid Capacity Expansion

TL;DR

**LFCR is showing signs of a turnaround with strong revenue growth and narrowing losses, making it a speculative buy for risk-tolerant investors.**

AI Summary

LIFECORE BIOMEDICAL, INC. reported a net loss of $9.991 million for the three months ended September 30, 2025, an improvement from the $16.230 million net loss in the comparable period ended August 25, 2024. Total revenues increased significantly to $31.109 million, up from $24.705 million in the prior comparable period, driven by both direct and related-party revenues. Operating loss narrowed to $3.067 million from $11.584 million, primarily due to a substantial decrease in selling, general, and administrative expenses from $14.785 million to $8.895 million, and a reduction in reorganization costs from $3.592 million to $1.571 million. The company completed its capacity expansion project during the quarter, which is expected to double aseptic capacity and increase depreciation expense by approximately $1.6 million per annum. Cash and cash equivalents increased to $18.856 million as of September 30, 2025, from $8.265 million as of May 25, 2025, despite a net decrease in cash and cash equivalents of $1.363 million during the quarter. The company also changed its fiscal year end from the last Sunday of May to December 31, effective May 26, 2025.

Why It Matters

Lifecore's significant revenue growth and reduced operating loss signal potential operational improvements, which could attract investors looking for turnarounds in the CDMO space. The completion of its aseptic capacity expansion project positions the company to capture more market share in complex sterile injectables, potentially intensifying competition for rivals. For employees, this expansion suggests job stability and growth opportunities. Customers could benefit from increased production capabilities and potentially faster time-to-market for their pharmaceutical products, making Lifecore a more attractive partner in a competitive industry.

Risk Assessment

Risk Level: medium — Despite improved operating results, the company reported a net loss of $9.991 million and a total stockholders' deficit of $10.537 million as of September 30, 2025. The significant related-party debt of $129.263 million and a related-party debt derivative liability of $25.491 million introduce financial complexity and potential conflicts of interest, contributing to a medium risk profile.

Analyst Insight

Investors should closely monitor LFCR's ability to leverage its new aseptic capacity to generate sustained profitability and positive cash flow. Evaluate future earnings reports for continued revenue growth and further reductions in net loss, especially considering the expected increase in depreciation expense from the capacity expansion.

Financial Highlights

debt To Equity

N/A

revenue

$31.109M

operating Margin

N/A

total Assets

$235.204M

total Debt

$198.418M

net Income

-$9.991M

eps

N/A

gross Margin

N/A

cash Position

$18.856M

revenue Growth

+25.9%

Revenue Breakdown

Key Numbers

• $31.109M — Total Revenues (Increased from $24.705M in prior comparable period, indicating strong top-line growth.)
• $(9.991)M — Net Loss (Improved from $(16.230)M in prior comparable period, showing progress in loss reduction.)
• $(3.067)M — Operating Loss (Significantly narrowed from $(11.584)M, reflecting improved operational efficiency.)
• $18.856M — Cash and Cash Equivalents (Increased from $8.265M as of May 25, 2025, strengthening liquidity.)
• $128.575M — Property, Plant and Equipment, net (Reflects completion of capacity expansion project, positioning for future growth.)
• $129.263M — Related Party Debt (Substantial debt to related parties, a key financial consideration.)
• 37,466,352 — Common Stock Outstanding (As of October 30, 2025, indicating current share count.)
• 60% — Revenue from United States (Primary geographic revenue source for the three months ended September 30, 2025.)
• $1.6M — Expected Annual Depreciation Increase (Due to completion of capacity expansion project, impacting future profitability.)
• $(10.537)M — Total Stockholders' (Deficit) Equity (Indicates a negative equity position, a financial concern.)

Key Players & Entities

• LIFECORE BIOMEDICAL, INC. (company) — registrant
• NASDAQ Global Select Stock Market (regulator) — exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• $9.991 million (dollar_amount) — net loss for three months ended September 30, 2025
• $16.230 million (dollar_amount) — net loss for three months ended August 25, 2024
• $31.109 million (dollar_amount) — total revenues for three months ended September 30, 2025
• $24.705 million (dollar_amount) — total revenues for three months ended August 25, 2024
• $1.6 million (dollar_amount) — expected annual increase in depreciation expense
• $18.856 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $129.263 million (dollar_amount) — related party debt, net of current portion, as of September 30, 2025

FAQ

Risk Factors

• Negative Stockholders' Equity [high — financial]: The company has a total stockholders' deficit of $(10.537)M as of September 30, 2025. This indicates that liabilities exceed assets, which can be a sign of financial distress and may impact the company's ability to secure future financing.
• Significant Related Party Debt [high — financial]: The company has substantial debt to related parties, totaling $129.263M as of September 30, 2025. The terms and conditions of these related-party transactions require careful scrutiny as they could present conflicts of interest or unfavorable terms.
• Capacity Expansion Depreciation Impact [medium — operational]: The completion of the capacity expansion project will increase annual depreciation expense by approximately $1.6M. While this is a positive step for future growth, it will negatively impact near-term profitability by increasing operating expenses.
• Net Loss Despite Revenue Growth [medium — financial]: Despite a significant increase in total revenues to $31.109M, the company reported a net loss of $9.991M for the three months ended September 30, 2025. Continued losses, even if reduced, raise concerns about long-term profitability.
• Dependence on Specific Markets [low — operational]: With 60% of revenue generated in the United States, the company may be exposed to risks associated with economic or regulatory changes within this specific geographic market.

Industry Context

Lifecore Biomedical operates in the contract development and manufacturing organization (CDMO) sector, serving the pharmaceutical and medical device industries. This sector is characterized by increasing demand for specialized manufacturing capabilities, particularly in aseptic processing. The industry faces competition from both large, established players and smaller, niche providers, with a strong emphasis on regulatory compliance and quality control.

Regulatory Implications

As a manufacturer of medical products, Lifecore Biomedical is subject to stringent regulations from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP) is critical. Any deviations or failures in quality control can lead to significant penalties, product recalls, and reputational damage, impacting revenue and operations.

What Investors Should Do

1. Monitor related-party transactions and debt
2. Analyze the impact of increased depreciation
3. Evaluate the path to profitability
4. Assess the balance sheet strength

Key Dates

• 2025-09-30: End of Fiscal Quarter — Reporting period for the 10-Q, showing improved revenue and reduced net loss compared to the prior year.
• 2025-05-25: Previous Fiscal Year End / Balance Sheet Date — Provides a comparative balance sheet date, showing an increase in cash and cash equivalents from $8.265M to $18.856M.
• 2025-05-26: Fiscal Year End Change Effective — The company changed its fiscal year end from the last Sunday of May to December 31, impacting future reporting periods.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception that have not been offset by net income. (Indicates the company has a history of net losses, with a current deficit of $(218.095)M as of September 30, 2025.)

Series A Redeemable Convertible Preferred Stock

A class of preferred stock that can be converted into common stock and has a redemption feature, meaning the holder or the company can force a sale under certain conditions. (Represents a significant liability on the balance sheet with a redemption value of $47.323M as of September 30, 2025.)

Contract Assets

Assets recognized when revenue is recognized before the company has an unconditional right to payment. (Represents $4.385M in assets as of September 30, 2025, related to revenue recognition timing.)

Debt derivative liability, related party

A liability arising from financial instruments (derivatives) linked to debt, specifically with related parties. (Represents a $25.491M liability as of September 30, 2025, indicating complex financial arrangements with related entities.)

Year-Over-Year Comparison

Compared to the prior comparable period, Lifecore Biomedical has demonstrated strong top-line growth with total revenues increasing by 25.9% to $31.109M. This revenue growth has contributed to a narrowed operating loss and a reduced net loss of $9.991M from $16.230M. A significant reduction in SG&A expenses and reorganization costs also aided profitability. However, the company's negative equity position persists, and new risks related to increased depreciation from capacity expansion have emerged.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share LFCR The NASDAQ Global Select

Filing Documents

• lfcr-20250930.htm (10-Q) — 889KB
• lfcr-20250930xexx101consen.htm (EX-10.1) — 68KB
• lfcr-20250930xexx102consen.htm (EX-10.2) — 62KB
• lfcr-20250930xexx311.htm (EX-31.1) — 11KB
• lfcr-20250930xexx312.htm (EX-31.2) — 10KB
• lfcr-20250930xexx321.htm (EX-32.1) — 6KB
• lfcr-20250930xexx322.htm (EX-32.2) — 5KB
• 0001005286-25-000148.txt ( ) — 7288KB
• lfcr-20250930.xsd (EX-101.SCH) — 53KB
• lfcr-20250930_cal.xml (EX-101.CAL) — 79KB
• lfcr-20250930_def.xml (EX-101.DEF) — 307KB
• lfcr-20250930_lab.xml (EX-101.LAB) — 762KB
• lfcr-20250930_pre.xml (EX-101.PRE) — 537KB
• lfcr-20250930_htm.xml (XML) — 874KB

Signatures

Signatures 36 i Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial statements (unaudited)

Item 1. Financial statements (unaudited) Consolidated Balance Sheets as of September 30, 2025 and May 25, 2025 1 Consolidated Statements of Operations for the Three Months Ended September 30, 2025 and August 25, 2024 2 Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Three Months Ended September 30, 2025 and August 25, 2024 3 Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2025 and August 25, 2024 4 Notes to the Consolidated Financial Statements 5 1 Organization, basis of presentation and summary of significant accounting policies 5 2 Income or loss per share 7 3 Segment reporting for single reportable segment 8 4 Accounts and note receivable 8 5 Inventory 9 6 Property, plant and equipment, net 10 7 Accrued expenses and other current liabilities 10 8 Commitments and contingencies 11 9 Debt 13 10 Equity 16 11 Revenue recognition 18 12 Stock-based compensation 19 13 Income taxes 20 14 Fair value of financial instruments 21 15 Leases 23 1 6 Related party transactions 25 1 Table of Contents LIFECORE BIOMEDICAL, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) September 30, 2025 May 25, 2025 ASSETS (unaudited) Current assets: Cash and cash equivalents $ 18,856 $ 8,265 Accounts receivable, net of allowance for credit losses of $ 804 and $ 1,351 17,573 15,151 Accounts receivable, related party 7,175 13,537 Current portion of note receivable — 8,000 Contract assets 4,385 6,979 Inventory 33,801 32,291 Prepaid expenses and other current assets 2,138 1,454 Total current assets 83,928 85,677 Property, plant and equipment, net of accumulated depreciation of $ 59,622 and $ 57,412 128,575 129,006 Goodwill 13,881 13,881 Intangible assets, net of accumulated amortization of $ 3,700 4,200 4,200 Other assets 4,620 6,578 Total assets $ 235,204 $ 239,342 LIABILITI

View Full Filing

View this 10-Q filing on SEC EDGAR